Search Results

Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials

Authors: Cao, Y.; Liao, C.; Tan, A.; Liu, L.; Mo, Z.; Gao, F.

Source: Colorectal Disease, Volume 12, Number 1, January 2010 , pp. 16-23(8)

Publisher: Blackwell Publishing

Severe palmar-plantar erytrodysesthesia after treatment with capecitabine

Authors: López, V; Martín, JM; Jordá, E

Source: Journal of the European Academy of Dermatology & Venereology, Volume 24, Number 1, January 2010 , pp. 106-108(3)

Publisher: Blackwell Publishing

Capecitabine: Subacute cutaneous lupus erythematosus in an elderly patient: case report

Source: Reactions, Volume 1, Number 1282, 2009-12-12 , pp. 15-15(1)

Publisher: Adis International

Capecitabine: Acute chest pain: case report

Source: Reactions, Volume 1, Number 1282, 2009-12-12 , pp. 15-15(1)

Publisher: Adis International

Capecitabine: Stomatitis and erythrodysaesthesia: case report

Source: Reactions, Volume 1, Number 1279, 2009-11-21 , pp. 12-12(1)

Publisher: Adis International

Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature

Authors: Garg, R.; Angus, E.; Fincher, S.

Source: Diabetic Medicine, Volume 26, Number 12, December 2009 , pp. 1308-1309(2)

Publisher: Blackwell Publishing

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer

Authors: Ryu, Min-Hee; Kang, Yoon-Koo

Source: Expert Review of Anticancer Therapy, Volume 9, Number 12, December 2009 , pp. 1745-1751(7)

Publisher: Expert Reviews

Much fluoropyrimidine toxicity may be avoidable through pretreatment testing for dihydropyrimidine dehydrogenase (DPD) polymorphisms

Source: Reactions, Volume 1, Number 1281, 2009-12-05 , pp. 5-5(1)

Publisher: Adis International

Capecitabine: Erythrodysaesthesia: case report

Source: Reactions, Volume 1, Number 1281, 2009-12-05 , pp. 11-11(1)

Publisher: Adis International

Capecitabine/lapatinib: Diarrhoea treated with probiotics: case report

Source: Reactions, Volume 1, Number 1277, 2009-11-07 , pp. 12-12(1)

Publisher: Adis International

Lapatinib plus letrozole for postmenopausal patients with advanced HER2⁺/HR⁺ breast cancer

Author: Guarneri, Valentina

Source: Expert Review of Anticancer Therapy, Volume 9, Number 11, November 2009 , pp. 1549-1557(9)

Publisher: Expert Reviews

Literature supports capecitabine for breast and colorectal cancer

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 7-7(1)

Publisher: Adis International

Gastric cancer drug market to grow through targeted therapies

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

Capecitabine: Hyperpigmentation and radiation recall phenomenon: case report

Source: Reactions, Volume 1, Number 1278, 2009-11-14 , pp. 11-11(1)

Publisher: Adis International

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

Authors: Okines, A. F. C.; Norman, A. R.; McCloud, P.; Kang, Y.-K.; Cunningham, D.

Source: Annals of Oncology, Volume 20, Number 9, 24 September 2009 , pp. 1529-1534(6)

Publisher: Oxford University Press

¹⁸⁸Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study

Authors: Lam, Marnix; Bosma, Tjitske; Rijk, Peter; Zonnenberg, Bernard

Source: European Journal of Nuclear Medicine and Molecular Imaging, Volume 36, Number 9, September 2009 , pp. 1425-1433(9)

Publisher: Springer

Novel agents for the treatment of adenocarcinoma of the pancreas

Authors: Mackenzie, R Pamela; McCollum, A David

Source: Expert Review of Anticancer Therapy, Volume 9, Number 10, October 2009 , pp. 1473-1485(13)

Publisher: Expert Reviews

Capecitabine: Palmar-plantar hyperpigmentation and erythrodysaesthesia: 3 case reports

Source: Reactions, Volume 1, Number 1274, 2009-10-17 , pp. 14-15(2)

Publisher: Adis International

Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin

Authors: Kim, Jong; Chae, Yee; Sohn, Sang; Moon, Joon; Ryoo, Hun; Bae, Sung; Kum, YoonSeop; Jeon, Seong; Lim, Kyoung-Hoon; Kang, Byung-Mo; Park, In-Ja; Choi, Gyu; Jun, Soo-Han

Source: Cancer Chemotherapy and Pharmacology, Volume 64, Number 5, October 2009 , pp. 953-960(8)

Publisher: Springer

A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial

Authors: Pisano, Carmela; Morabito, Alessandro; Sorio, Roberto; Breda, Enrico; Lauria, Rossella; Gebbia, Vittorio; Scaltriti, Laura; Scalone, Simona; Zagonel, Vittorina; Greggi, Stefano; Beneduce, Gerardo; Losito, Simona; Gallo, Ciro; Maio, Massimo; Forestieri, Valeria; Pignata, Sandro

Source: Cancer Chemotherapy and Pharmacology, Volume 64, Number 5, October 2009 , pp. 1021-1027(7)

Publisher: Springer